Our Pipeline
Using our proprietary drug discovery platform, we are developing a pipeline of first in class precision therapeutics that regulate key muscle proteins to address a broad array of genetically characterized muscle disorders. We have retained global development and commercialization rights to all of our programs. Our current pipeline is summarized below.
Program/TARGET
Indication
Preclinical
Phase 1
Phase 2
Phase 3
EDG-7500
Undisclosed Target
HCM
Preclinical
Phase 1
Phase 2
Phase 3
EDG-003
Undisclosed Target
Cardiovascular
Preclinical
Phase 1
Phase 2
Phase 3
DMD - Duchenne muscular dystrophy
BMD - Becker muscular dystrophy
HCM - Hypertrophic cardiomyopathy
LGMD - Limb-girdle muscular dystrophy